ArticleCurrent oncology (Toronto, Ont.)2023

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Rebekah Rittberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.